Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Advanced Solid Tumors
Interventions: CS2009, Pemetrexed, Carboplatin, Paclitaxel, Etoposide, Nab-paclitaxel, Oxaliplatin, Capecitabine, Docetaxel, Leucovorin, 5-FU, Cisplatin, Gemcitabine, Irinotecan; Drug
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Irving, Texas

Conditions: Fatigue
Interventions: Fisetin followed by Placebo, Placebo followed by Fisetin; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 65 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Hodgkin Lymphoma
Interventions: Polatuzumab vedotin; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 12 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM), Glioma, Central Nervous System Diseases, Brain Cancer
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 38
States / cities: Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 33 more

Conditions: Chronic Pain Due to Cancer, Pain Catastrophizing
Interventions: Empowered Relief Course (Zoom); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 120 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Solid Tumor, Solid Tumor, Adult, Solid Tumor, Unspecified, Adult
Interventions: CONVO intervention; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: New York, New York • The Bronx, New York

Conditions: Suicide Prevention
Interventions: Pilot Intervention, Treatment as Usual; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 10 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Centralia, Washington • Mountlake Terrace, Washington • Olympia, Washington

Conditions: Metastatic Colorectal Cancer (CRC)
Interventions: Regorafenib (BAY 73-4506), 5FU/LV, Bevacizumab, Trifluridine-tipiracil; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin
Interventions: Miltenyi CliniMACS Prodigy ® system; Device
Lead sponsor: University of Florida; Other
Eligibility: 6 Months to 39 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
Interventions: Ibrutinib, Pembrolizumab, Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York

Conditions: Degenerative Cervical Myelopathy
Interventions: Transcutaneous spinal cord stimulation, Balance and Gait Training; Device · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Repair of Dura Mater
Interventions: Not listed
Lead sponsor: Collagen Matrix; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, EBV Related Non-Hodgkin's Lymphoma
Interventions: Dose Level 1A: 2 x 10^7 cells/m2, Dose Level 2A: 6 x 10^7 cells/m2, Dose Level 2B: 6 x 10^7 cells/m2, Dose Level 3B: 2 x 10^8 cells/m2, Dose Level 3A: 2 x 10^8 cells/m2, Dose Level 1B: 2 x 10^7 cells/m2; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2042
U.S. locations: 4
States / cities: Houston, Texas

Conditions: Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 27
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 21 more

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 20
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 15 more

Conditions: Lymphatic Malformation, Generalized Lymphatic Anomaly (GLA), Central Conducting Lymphatic Anomaly, CLOVES Syndrome, Gorham-Stout Disease ("Disappearing Bone Disease"), Blue Rubber Bleb Nevus Syndrome, Kaposiform Lymphangiomatosis, Kaposiform Hemangioendothelioma/Tufted Angioma, Klippel-Trenaunay Syndrome, Lymphangiomatosis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anxiety Disorders
Interventions: Project EMPOWER, Being Brave Parent Education, Sharing Feelings; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoarthritis
Interventions: Sustained Acoustic Device with 2.5% Diclofenac Patch, 2.5% Diclofenac Patches; Device · Drug
Lead sponsor: ZetrOZ, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: ASCVD Management
Interventions: Pharmacy Intern Counseling; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Aging
Interventions: Low dose ASA, Control; Drug · Other
Lead sponsor: Penn State University; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment; Device · Drug
Lead sponsor: Galvani Bioelectronics; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 12
States / cities: Anniston, Alabama • Covina, California • Whittier, California + 8 more

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2041
U.S. locations: 424
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 318 more

Conditions: Gastroesophageal Reflux, Sleeve Gastrectomy, Bariatric Surgery Complication
Interventions: EndoFLIP measurement; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 2
States / cities: Orlando, Florida • Rochester, Minnesota

Search by objective public record fields.

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Empowered Relief® for Cancer Survivors With Chronic Pain

Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values

Adapting a Brief Suicide Intervention for Pediatric Primary Care: Enhancing Uptake and Impact

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Stimulation-based Therapy to Improve Balance in DCM

Post-Market Clinical Investigation Plan - Collagen Dura Membranes (DM & DMO)

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Lymphatic Anomalies Registry for the Assessment of Outcome Data

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

Online Parent Education for Child Anxiety

Sustained Acoustic Medicine for Osteoarthritis Pain

Optimizing Non-statin Agents for ASCVD

Identification of Critical Thermal Environments for Aged Adults

ConsideRAte Study - Splenic Stimulation for RA

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction